CannabisNewsBreaks

FridayDec 08, 2017 12:42 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTech™ Shines in Vegas Lights

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) attracted a lot of attention in Las Vegas at this year’s Marijuana Business Conference & Expo due to increased awareness about potential health benefits of cannabinoids and an increased demand for improved CBD-based edibles. A recent article highlights keen interest in Lexaria’s patented DehydraTECH™ delivery technology, stating, “Lexaria’s proprietary technology has been awarded patents in the U.S. and Australia, and it has patents pending in more than 40 other countries. Furthermore, it is the only company in the world to date that has a patent allowed for the oral delivery of all non-psychoactive cannabinoids,…

Continue Reading

FridayDec 08, 2017 8:31 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Retains Medical Director to Advise Cannabis Research Programs

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning reported that the company has hired Dr. M. Scott Alexander as a medical director. Alexander’s role will be to confirm the medical integrity of cannabis research programs conducted by the company’s subsidiary, Cannevert Therapeutics Ltd. In addition, Alexander will develop a medical affairs strategy to support cannabis strains currently in development. “Dr. Alexander brings a wealth of medical knowledge, a clear understanding of current clinical practice and regulatory needs, and a pledge to educate all stakeholders about therapeutic strains that are based on Cannevert’s experimental evidence,” Veritas CEO Dr. Lui…

Continue Reading

WednesdayDec 06, 2017 3:28 pm

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Featured in Visual Capitalist Company Spotlight

Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) was recently highlighted in a company spotlight article by Visual Capitalist. The article features an infographic that breaks down the company’s development of novel cannabinoid-based therapies from start to finish. Among other areas of interest, Visual Capitalist provided an in-depth look into InMed's Bioinformatics assessment tool, Biosynthesis cannabinoid manufacturing process, and drug pipeline of new cannabinoid treatments. To view the full infographic, visit http://cnw.fm/5afgV About InMed InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery…

Continue Reading

TuesdayDec 05, 2017 8:29 am

CannabisNewsBreaks – Veritas Pharma Inc.’s (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Cannevert Subsidiary Inks Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico

Emerging pharmaceutical and IP development company Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) today announced that its research arm, Cannevert Therapeutics Ltd. (“CTL”), has signed a Material Transfer Agreement with the Institute for Medical Cannabis Corporation of Puerto Rico. Per the agreement, the Institute for Medical Cannabis will provide CTL with particular cannabis strains for upcoming human studies in the US territory. “We are pleased that Cannevert has identified a reputable producer that is focused on providing certified quality products, educating the medical community on the potential benefits of cannabis, and conducting clinical research on its products. They will…

Continue Reading

MondayDec 04, 2017 1:10 pm

CannabisNewsBreaks – Cannabis Demand in Canada Creates Considerable Opportunity for ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)

As Canada prepares for the legalization of recreational marijuana in July 2018, analysts are noting a shortage of supplies compared to expected demand for cannabis products. The demand is expected to exceed about 1.3 million pounds, easily outpacing current annual production of 20,000 pounds by the country’s licensed producers. That creates tremendous opportunities for Canada’s top cultivators with the ability to expand their operations and increase supply. An article discussing this reads: “ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), has been licensed in good standing since 2014 with no history of product recalls, and proprietary computer-controlled production systems that have bolstered…

Continue Reading

MondayDec 04, 2017 9:04 am

CannabisNewsBreaks – Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Provides 2018 Strategy Update Regarding Growth Plans

Licensed Canadian cannabis cultivation company Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) this morning provided an update regarding its growth plans for 2018. The company’s incoming president and CEO Nick Dean intends to focus on meeting the expected surge in demand in the recreational cannabis sector through strategic partnerships and by increasing Emblem’s total production capacity. Dean also intends to ramp up patient acquisition in the medical cannabis market utilizing the company’s strengths and quality products. “Ultimately it’s about being relentlessly driven to deliver a strong return on investment and a solid balance sheet. We will also be mindful of strategic…

Continue Reading

FridayDec 01, 2017 11:41 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Posts Q3 Results, Operational Update

Abcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) recently released financial results for the three and nine months ended September 30, 2017. Among other highlights from the third quarter, the company reported $43.4 million in cash, cash equivalents and marketable securities which provides a strong position for expansion plans for its high-tech Vanluven facility. Abcann also reported revenues of $614,000 for the nine months ended September 30, 2017, a considerable increase compared to $211,00 during the same period in 2016. Additionally, the company provided an update on operations, including the company’s strategy moving forward. “ABcann’s vision is to create a successful…

Continue Reading

FridayDec 01, 2017 10:46 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Stock, Option and Warrant Transactions

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced various stock, option and warrant transactions. The news release states, “Following issuance of these common shares, Lexaria will have 69,674,919 common shares issued and outstanding. No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.” No shares were sold or registered in the United States. In addition, John Docherty, President of Lexaria Bioscience Corp., recently issued a clip discussing the company's technology…

Continue Reading

TuesdayNov 28, 2017 9:33 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Research Arm’s Patent Filing for Use of Specific Cannabis Strain Acknowledged by US Patent Office

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) today announced that its research arm, Cannevert Therapeutics Ltd. (“CTL”), received an acknowledgement letter with the filing number of US 62/558,021 from the US Patent and Trademark Office (“USPTO”) for the filing it made in September for use of a specific cannabis strain to enhance the actions of opioid analgesics.  Veritas CEO, Dr. Lui Franciosi commented, “We are pleased with Cannevert’s latest submission to protect its discovery of a cannabis strain that could potentially reduce the dose and side effects of clinically used opioids while maintaining a good pain relieving effect for…

Continue Reading

MondayNov 27, 2017 9:15 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Set to Present at LD Micro Main Event; Reports Warrant Exercise

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it will be presenting at the upcoming 10th annual LD Micro Main Event taking place December 5-7 in Los Angeles, California. Additionally, the company is filing its annual Form 10K which includes financial statements that will be available today at the Securities and Exchange Commission's website (www.sec.gov). Lexaria also said that through the exercise of warrants and a compensation option certificate previously granted, the company has received US $118,913. The compensation option certificate was exercised at…

Continue Reading